Chimeric Antigen Receptor (CAR) T cell Therapy in Paediatric ALL – a potential curative treatment for relapsed/ refractory disease

Loading Events
  • This event has passed.
Description

Chimeric Antigen Receptor (CAR) T cell Therapy in Paediatric ALL – a potential curative treatment for relapsed/ refractory disease
Tuesday, 23rd March at 1pm.

Paul Lynam, Chief Medical Scientist in the Haematopoietic Stem Cell Transplant Laboratory (HSCT) in Children’s Health Ireland at Crumlin since 2009 will present “Chimeric Antigen Receptor (CAR) T cell Therapy in Paediatric ALL – a potential curative treatment for relapsed/ refractory disease.”

Outcomes for paediatric patients diagnosed with Acute Lymphoblastic Leukaemia have dramatically improved over the past few decades with upwards of 80% of patients being cured with chemotherapy alone. There remains a cohort of patients (15-20%), however, who present with refractory disease or who suffer disease relapse during treatment.  Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) is the preferred treatment option for high-risk patients who achieve a second complete response post relapse but the prognosis for those who are not eligible for HSCT or for those that relapse post-HSCT remains very poor.  Immunotherapies such as CAR-T therapy have emerged as a strategy to treat refractory or relapsed paediatric ALL .  CAR-T therapy utilises a patient’s own T cells by genetically modifying them to specifically target and destroy malignant cells. Very promising results have been observed using this technology with remission rates as high as 90% reported in some trials. Introduction of CAR-T therapy as a treatment option for relapsed or refractory paediatric ALL patients offers hope for a patient cohort with otherwise very limited treatment options.

Booking is now open through www.acslm.ie
CPD / EVENTS / Login as member or create a non-member account

Members Booking Help

Non-members Booking Help

Start Date - End Date

Mar 15, 2021 - Mar 26, 2021

Start Time - End Time

8:00 am - 5:00 pm

Share This